21st Jun 2006 14:17
21 June 2006Results of the Annual General MeetingShire plc AGM - 2006Shire plc held its Annual General Meeting today. All resolutions were put tothe meeting and approved on a show of hands. The proxy votes received for themeeting are set out below: For* Against Abstentions** 1. To receive and consider 359,071,857 675,088 1,574,434 the directors' report and accounts for the (99.81%) (0.19%) year ended 31 December 2005 2. To re-elect Dr James 360,237,140 617,865 466,374 Henry Cavanaugh as a director (99.83%) (0.17%) 3. To re-elect Mr Robin 360,460,134 403,668 457,577 William Turnbull Buchanan as a director (99.89%) (0.11%) 4. To re-elect Mr Matthew 358,012,655 1,004,977 2,303,747 William Emmens as a director (99.72%) (0.28%) 5. To re-elect the 357,125,147 2,752,824 1,443,408 Honourable James Andrews Grant as a (99.24%) (0.76%) director 6. To re-elect Mr David 358,720,911 2,140,994 459,474 John Kappler as a director (99.41%) (0.59%) 7. To elect Mr Patrick 360,310,235 551,670 459,474 Jean Mark Langlois as a director (99.85%) (0.15%) 8. To re-elect Mr Ronald 355,747,898 552,524 5,020,957 Maurice Nordmann as a director (99.84%) (0.16%) 9. To re-elect Dr Barry 354,069,599 2,231,923 5,019,857 John Price as a director (99.37%) (0.63%) 10. To re-elect Mr Angus 358,109,095 916,203 2,296,081 Charles Russell as a director (99.74%) (0.26%) 11. To re-appoint Deloitte 350,604,574 6,521,791 4,195,014 & Touch LLP as Auditors (98.17%) (1.83%) 12. To authorise the Audit 359,770,712 1,187,866 362,801 Committee to determine the remuneration of the (99.67%) (0.33%) Auditors 13. To approve the 339,634,086 11,273,314 10,413,979 Directors' Remuneration Report (96.79%) (3.21%) 14. To authorise the 355,037,733 6,159,314 124,332 allotment of shares (98.29%) (1.71%) 15. To authorise the 358,499,820 2,669,655 152,904 disapplication of pre-emption rights (99.26%) (0.74%) 16. To authorise market 361,026,133 238,054 57,192 purchases (99.93%) (0.07%) 17. To authorise donations 354,116,165 5,286,233 1,918,981 to EU political organisations and EU (98.53%) (1.47%) political expenditure * These figures include discretionary votes** Abstentions are not counted in the proportion of votes "for" or "against"For further information please contact:Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsSHIRE PLCShire's strategic goal is to become the leading specialty pharmaceuticalcompany that focuses on meeting the needs of the specialist physician. Shirefocuses its business on central nervous system, gastrointestinal, generalproducts and human genetic therapies. The structure is sufficiently flexible toallow Shire to target new therapeutic areas to the extent opportunities arisethrough acquisitions. Shire believes that a carefully selected portfolio ofproducts with a strategically aligned and relatively small-scale sales forcewill deliver strong results.Shire's focused strategy is to develop and market products for specialtyphysicians. Shire's in-licensing, merger and acquisition efforts are focused onproducts in niche markets with strong intellectual property protection eitherin the US or Europe.For further information on Shire, please visit the Company's website: www.shire.com. Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDSHIRE PLCRelated Shares:
Shire